Advertisement
Advertisement
ELUT
Elutia Inc. Class A Common Stock
0.81
USDSponsored
-0.04
-5.06%
Sep 22, 15:54 UTC -4
Closed
Pre-Market
0.81
0.00
-0.02%
ELUT Earnings Reports
Positive Surprise Ratio
ELUT beat 8 of 24 last estimates.
33%
Next Report
Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
$1.02M
/-$0.15
Implied change from Q2 26 (Revenue/ EPS)
-57.97%
/-11.76%
Implied change from Q3 25 (Revenue/ EPS)
-69.30%
/+66.67%
Elutia Inc. Class A Common Stock earnings per share and revenue
On Aug 13, 2026, ELUT reported earnings of -0.17 USD per share (EPS) for Q2 26, missing the estimate of -0.15 USD, resulting in a -11.11% surprise. Revenue reached 2.43 million, compared to an expected 2.96 million, with a -17.95% difference. The market reacted with a +9.38% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 4 analysts forecast an EPS of -0.15 USD, with revenue projected to reach 1.02 million USD, implying an decrease of -11.76% EPS, and decrease of -57.97% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
FAQ
What were Elutia Inc. Class A Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Elutia Inc. Class A Common Stock reported EPS of -$0.17, missing estimates by -11.11%, and revenue of $2.43M, -17.95% below expectations.
How did the market react to Elutia Inc. Class A Common Stock's Q2 2026 earnings?
The stock price moved up 9.38%, changed from $0.86 before the earnings release to $0.94 the day after.
When is Elutia Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for Elutia Inc. Class A Common Stock's next earnings report?
Based on 4
analysts, Elutia Inc. Class A Common Stock is expected to report EPS of -$0.15 and revenue of $1.02M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.